By Dennis Thompson 

HealthDay Reporter

WEDNESDAY, April 26, 2023 (HealthDay News) — An extended-release version of a Parkinson’s disease drug could provide more stable relief for patients with the movement disorder, new clinical trial data show.

The new formulation of levodopa, called IPX203, extended the duration of patients’ “on time” — the amount of time the medication is working and symptoms are lessened, researchers reported this week at the American Academy of Neurology’s annual meeting, in Boston.

Three oral doses of IPX203 a day worked slightly better than five doses of standard levodopa, with patients’ “on time” running about a half-hour longer, said lead…


By prebo

Leave a Reply

Your email address will not be published. Required fields are marked *